The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
20020902: CompuCredit Corporation; Federated Department Stores Inc.
20020898: Electronic Data System Corporation; Loudcloud, Inc.
20020893: Group 1 Automotive, Inc.; Miller Trust of 1980 (restated)
20020869: GS Capital Partners 2000, L.P.; Atlantic Equity Partners International II, L.P.
20020858: South African Breweries plc; Philip Morris Companies Inc.
20020853: Stryker Corporation; Tyco International Ltd.
20020838: DRS Technologies, Inc.; Eaton Corporation
Biovail Corporation
The Commission charged Biovail Corporation with illegally acquiring an exclusive patent license for Tiazac, a pharmaceutical used to treat high blood pressure and chronic chest pain. The complaint further alleged that Biovail, in an effort to maintain its monopoly, wrongfully listed the acquired license in the U.S. Food and Drug Administration’s “Orange Book” for the purpose of blocking generic competition to its branded Tiazac. The consent order requires Biovail to divest part of its exclusive rights to DOV; prohibits the firm from taking any action that would trigger additional statutory stays on final FDA approval of a generic form of Tiazac; and also prohibits Biovail from wrongfully listing any patents in the Orange Book for a product for which the company already has an New Drug Application from the FDA.